Stocks that have missed out on this year's market rally could be solid contenders for a rebound, according to Goldman Sachs. The major averages have had a rocky start to April, but they kicked off 2024 on a strong note. The S & P 500 jumped more than 10% in the first quarter. Heading into the second quarter, Goldman searched for buy-rated names in its coverage universe that could win big going forward.
"We think the bull case is fairly obvious, with APTV's product portfolio representing one of the best levered to megatrends within our coverage universe of parts suppliers," he wrote. Biopharmaceutical titan Pfizer was another name Goldman highlighted as a compounding buy. Although the majority of analysts covering the stock have it at a hold rating, the potential upside for the stock is nearly 19% from here, per LSEG. Pfizer has slipped 9% this year.
Source: News Formal (newsformal.com)
Lamb Weston Holdings Inc Pfizer Inc Aptiv PLC Stock Markets Investment Strategy Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: cnnbrk - 🏆 393. / 55 Read more »
Goldman Sachs hedge fund clients are piling back into crypto this yearMax Minton, Goldman Sach’s head of digital assets, says an increasing number of his firm’s hedge fund clients are making the jump back into crypto following the approval of spot Bitcoin ETFs.
Source: Cointelegraph - 🏆 562. / 51 Read more »
Source: TheBlock__ - 🏆 464. / 53 Read more »
Source: ForbesTech - 🏆 318. / 59 Read more »
Source: Crypto_Potato - 🏆 568. / 51 Read more »
Source: NYAmNews - 🏆 269. / 63 Read more »